Ask AI
ProCE Banner Activity

Hemophilia Hemostatic Rebalancing Therapies: Insight for Patient Care

Clinical Thought

Hemophilia experts address key points on the integration of hemostatic rebalancing therapies into the clinical care of patients with hemophilia.

Released: April 06, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

Target Audience

This educational activity is intended for hematologists and other healthcare professionals who care for patients with hemophilia. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to justify the use of hemostatic rebalancing therapies by explaining their mechanisms of action, clinical indications, and patient selection criteria in the context of moderate to severe hemophilia

  • Interpret current clinical trial data on rebalancing therapies and apply this evidence to guide treatment selection for patients with and without inhibitors

  • Assess individual patient characteristics to identify candidates for rebalancing therapies and develop personalized prophylaxis management strategies that optimize clinical outcomes

  • Evaluate the risks and benefits of integrating rebalancing agents into clinical care, including thrombotic risk mitigation, monitoring strategies, and shared decision-making approaches

Disclosure

Primary Author

Angela C. Weyand, MD: consultant/advisor/speaker: Alnylam, Bayer, Genentech, Hema Biologics, Hemab, Novo Nordisk, Pfizer, Roche, Sanofi, SeraGene, Sobi, Spark, Takeda; researcher: Genentech, Hemab, Sanofi, Spark Biomedical, Vega.

Guy Young, MD: consultant/advisor/speaker: Alnylam, Bayer, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics, Hemab, Novo Nordisk, Octapharma, Pfizer, Sanofi, Takeda.